BioCentury | Nov 24, 2003
Clinical News

Arginine deiminase: Phase III

...said it received an SPA from the FDA for a similar U.S. Phase III trial. Phoenix Pharmacologics Inc....
BioCentury | Nov 17, 2003
Clinical News

Phoenix starts liver cancer Phase III

Phoenix Pharmacologics (Lexington, Ky.) started an Italian open-label Phase III trial of its recombinant pegylated arginine deiminase (ADI-PEG 20) targeted enzyme therapy in 80 patients with terminal liver cancer. The trial, which will measure survival...
BioCentury | Oct 20, 2003
Emerging Company Profile

Corporate Profile

Phoenix Pharmacologics Inc. Lexington, Ky. Technology: Recombinant proteins and peptides Disease focus: Cancer, inflammation Clinical status: Phase II Founded: 1996 by Mike Clark and John Bomalaski Corporate partners: TDW University collaborators: None Employees: 18 Funds...
BioCentury | Oct 20, 2003
Emerging Company Profile

Phoenix: A better enzyme

Phoenix Pharmacologics Inc. is trying to expand the uses of two clinically validated enzymatic therapy concepts. The company's lead product, recombinant pegylated arginine deiminase (ADI-PEG 20), applies the concept behind the anti-cancer enzyme therapy asparaginase...
BioCentury | Aug 4, 2003
Clinical News

Arginine deiminase: Phase II

...that the average survival was >5 times the historical life expectancy for comparable HCC patients. Phoenix Pharmacologics Inc....
Items per page:
1 - 5 of 5
BioCentury | Nov 24, 2003
Clinical News

Arginine deiminase: Phase III

...said it received an SPA from the FDA for a similar U.S. Phase III trial. Phoenix Pharmacologics Inc....
BioCentury | Nov 17, 2003
Clinical News

Phoenix starts liver cancer Phase III

Phoenix Pharmacologics (Lexington, Ky.) started an Italian open-label Phase III trial of its recombinant pegylated arginine deiminase (ADI-PEG 20) targeted enzyme therapy in 80 patients with terminal liver cancer. The trial, which will measure survival...
BioCentury | Oct 20, 2003
Emerging Company Profile

Corporate Profile

Phoenix Pharmacologics Inc. Lexington, Ky. Technology: Recombinant proteins and peptides Disease focus: Cancer, inflammation Clinical status: Phase II Founded: 1996 by Mike Clark and John Bomalaski Corporate partners: TDW University collaborators: None Employees: 18 Funds...
BioCentury | Oct 20, 2003
Emerging Company Profile

Phoenix: A better enzyme

Phoenix Pharmacologics Inc. is trying to expand the uses of two clinically validated enzymatic therapy concepts. The company's lead product, recombinant pegylated arginine deiminase (ADI-PEG 20), applies the concept behind the anti-cancer enzyme therapy asparaginase...
BioCentury | Aug 4, 2003
Clinical News

Arginine deiminase: Phase II

...that the average survival was >5 times the historical life expectancy for comparable HCC patients. Phoenix Pharmacologics Inc....
Items per page:
1 - 5 of 5